NCT06314685进行中（未招募）3 期
A Single-center, Randomized, Blind, Positive Control Phase III Clinical Trial to Evaluate Immunogenicity and Safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged From 6 Months to 5 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,450
- 试验地点
- 1
- 主要终点
- Antibody positive conversion rate
研究概览
简要总结
The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.
详细描述
This is a Phase III, single center, randomized, blind, positive control clinical trial conducted in Hunan Province, China. The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old. A total of 2450 subjects were included, divided into three age groups: 6-11 months old (700 subjects), 12-23 months old (1050 subjects), and 2-5 years old (700 subjects).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Months 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For primary immunization stage:
- •Subjects aged 6 months-5 years;
- •Subjects should be full-term (37-42 weeks of gestation) and their birth weight should meet the requirements (2500g ≤ body weight ≤ 4000g);
- •Axillary body temperature ≤ 37.0 ℃;
- •The guardian of the subject voluntarily agrees to the child's participation in the study and signs an informed consent form;
- •The guardians of the subjects have the ability to understand the research procedures and participate in all planned follow-up visits;
- •Infants and young children aged 6 to 23 months have not received the meningococcal conjugate vaccine. If they have been vaccinated with group A meningococcal polysaccharide vaccine, the interval between vaccination and the previous dose should exceed 3 months;
- •Children aged 2-5 who have not been vaccinated with meningococcal conjugate vaccine, if they have been vaccinated with meningococcal polysaccharide vaccine (including group A meningococcal polysaccharide vaccine, group A and C meningococcal polysaccharide vaccine, and group ACYW135 meningococcal polysaccharide vaccine), the interval between the last dose should exceed 12 months;
- •Subjects had no vaccination history of other live attenuated vaccines (such as BCG vaccine, live attenuated polio vaccine, rotavirus vaccine, etc.) within 14 days before vaccination, and no vaccination history of other non live vaccines (such as hepatitis B vaccine, inactivated polio vaccine, DPT vaccine, etc.) within 7 days.
- •Subjects who have not been vaccinated with meningococcal group A and C conjugate vaccine at the aged of 3-5 months;
- •Subjects who had no history of other live vaccines within 14 days before vaccination and no history of other inactivated vaccines within 7 days;
- •For booster immunization stage (applicable to the 6-11 month age group):
- •Infants and young children who have been enrolled in this clinical trial between 6 and 11 months of age and have reached the age of 18 months;
- •Infants and young children who have completed basic immunization in this clinical trial;
- •According to the opinions of the researchers, the subjects and their guardians are able to comply with the requirements of the clinical trial protocol.
- •For immune persistence stage (applicable to the 12-23 month age group):
- •Children who have been enrolled in this clinical trial at 12-23 months of age and have completed basic immunization for 12 months; According to the researcher's opinion, the subjects and their guardians are able to comply with the requirements of the clinical trial protocol.
排除标准
- •For primary immunization stage:
- •Have a history of severe allergic reactions that require medical intervention; Have a history of allergies to vaccines or vaccine ingredients (such as lactose, sodium chloride, tetanus toxoids, etc.), and other serious adverse reactions to vaccines;
- •Has contraindications for intramuscular injection such as thrombocytopenia, any coagulation dysfunction, or undergoing anticoagulant therapy;
- •Has severely abnormal labor (dystocia, instrumental delivery, excluding cesarean section), or history of asphyxia, neurological damage, in vitro fertilization or multiple pregnancy, pathological jaundice (only applicable to infants and young children aged 6-11 months);
- •Suffering from serious congenital malformations or chronic diseases that may interfere with the progress or completion of the study (including but not limited to Down's syndrome, thalassemia (the first degree relatives in the family are thalassemia or gene carriers of thalassemia), heart disease, kidney disease, diabetes, autoimmune diseases (repeated perianal abscesses), hereditary allergies, Guillain Barre syndrome, etc.);
- •Infectious diseases with clinical or serological evidence, such as tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection or HIV infected parents;
- •Any situation resulting in splenomegaly, splenectomy, or functional splenomegaly;
- •Has a history of convulsions, epilepsy, encephalopathy, and mental illness (including family history);
- •Within 3 days prior to the first dose of the vaccine, there was an acute illness or acute exacerbation of a chronic disease, or the use of antipyretic, analgesic, and anti allergic drugs (such as acetaminophen, ibuprofen, aspirin, etc.);
- •Congenital or acquired immunodeficiency; Or receive systemic corticosteroid treatment (any medication route, ≥ 2mg/kg/day) for ≥ 14 days within 3 months prior to enrollment, such as prednisone, inhaled steroids budesonide, fluticasone, etc; Or being using other immunosuppressants such as cyclosporine, tacrolimus, etc. before enrollment;
- •Has given immunoglobulin and/or any blood products (except hepatitis B immunoglobulin) within 3 months before enrollment;
- •Plan to move before the end of the study visit or leave the local area for a long time during the scheduled study visit;
- •Plan to participate or be participating in any other drug clinical research;
- •According to the researcher's judgment, there are any other factors that are not suitable for the subjects to participate in the clinical trial.
- •For booster immunization stage (applicable to the 6-11 month age group) and immune persistence stage (applicable to the 12-23 month age group):
- •Subjects in the experimental group aged 6-11 months received any meningococcal vaccine before blood serum collection at 18 months old after completing basic immunization;
- •Subjects in the 12-23 month age group were vaccinated with any meningococcal vaccine before completing blood collection at 12 month post-completion of primary immunization schedule;
- •After participating in this clinical trial, the subjects are known or suspected to have immunological deficiencies, including being treated with immunosuppressants (such as radiation therapy, chemotherapy, corticosteroids, anti metabolic drugs, cytotoxic drugs, etc.) and HIV infection;
- •Subjects in the experimental group aged 6-11 month old were given immunoglobulin and/or any blood products (except hepatitis B immunoglobulin) within 3 months before the booster immunization.
- •According to the researcher's judgment, there are any other factors that are not suitable for the subjects to participate in the clinical trial
结局指标
主要结局
Antibody positive conversion rate
时间窗: 30 day after primary immunization
Immunogenicity study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine as assessed by positive conversion rate (4-fold increase)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 MonthsMeningitis, MeningococcalNCT05252715Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd1,200
进行中（未招募）
3 期
Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 MonthsHealthy PopulationNCT06314659Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd630
已完成
2 期
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 MonthsMeningitis, MeningococcalNCT05229536Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd720
已完成
3 期
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate VaccineMeningitisNCT02003495Beijing Minhai Biotechnology Co., Ltd2,195
已完成
2 期
Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002MeningitisNCT01661738Hualan Biological Engineering, Inc.360